Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to CL2022001461ApriorityCriticalpatent/CL2022001461A1/en
Publication of CL2022001461A1publicationCriticalpatent/CL2022001461A1/en
La divulgación proporciona anticuerpos que se fijan a CD40, que incluyen un anticuerpo humanizado. Los anticuerpos se fijan a CD40 y no exhiben actividad agonista de CD40. Los anticuerpos pueden comprender un dominio Fc de IgG1 modificado y exhibir activación mínima de células dendríticas inmaduras. Se proporcionan composiciones que comprenden anticuerpos, métodos de uso para el tratamiento de enfermedades que incluyen la actividad de CD40, y el uso en la preparación de un medicamento para el tratamiento de una enfermedad que incluyen la actividad de CD40.The disclosure provides antibodies that bind to CD40, including a humanized antibody. The antibodies bind to CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for the treatment of diseases that include CD40 activity, and use in the preparation of a medicament for the treatment of a disease that includes CD40 activity are provided.
CL2022001461A2022-06-022022-06-02
Antagonistic monoclonal antibodies against cd40 and their uses
CL2022001461A1
(en)
Pharmaceutical composition comprising a) the humanized b-ly1 antibody (anti-cd20 / human b-lymphocyte / bp35 restricted referencing antigen, type ii), b) optionally from 0.001% to 1% w / v of at least one surfactant, and c) 1 to 100 mm of a buffer; use to treat cd20-related diseases.